Market Overview

Morgan Stanley Reports on Athenahealth


Morgan Stanley commented on Athenahealth (NASDAQ: ATHN) in a report released today. In the report, Morgan Stanley was cautious in its assessment of the stock.

Morgan Stanley writes, "Management characterized Anodyne as “a year behind” schedule due to the health issues of its CEO, but indicated confidence with regards to the potential of Anodyne as “a sales lead generator” by identifying physician practices that are under-performing with respect to revenue cycle efficiencies. Management bullish on ATHN's long-term gross margin runway, despite the conservative CY11 guidance given in December, the high-end of which points to only 75 basis points of YOY expansion. Management indicated that there is potential for a ~70% non-GAAP gross margin in the long term (versus ~63% now) through the scaling of its physician network and automating manual processes. This could represent upside to our 2015E gross margin estimate of~65%."

Morgan Stanley currently has an Underweight rating on Athenahealth. Shares of Athenahealth closed at $45.31 yesterday, down $0.06 from the opening bell.


Related Articles (ATHN)

View Comments and Join the Discussion!

Posted-In: Morgan StanleyAnalyst Color Analyst Ratings

Latest Ratings

CAMTStifelInitiates Coverage On19.0
ELMDNorthland Capital MarketsInitiates Coverage On15.0
DKNGUBSInitiates Coverage On52.0
DIODTruist SecuritiesInitiates Coverage On84.0
TGTArgus ResearchUpgrades205.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at